Articles by Rachel Narozniak, MA
Gecacitinib improved spleen volume, symptoms, and anemia in JAK inhibitor–naive MF, regardless of baseline anemia severity.
Zanubrutinib shows durable efficacy and safety in high-risk CLL/SLL, regardless of 17p deletion, per 5-year SEQUOIA data.
Asciminib shows safety and efficacy as a 2nd-line treatment in CML-CP without T315I, per interim phase 2 ASC2ESCALATE results
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.